Needham maintains Buy rating on Immix Biopharma, $30 price target
Needham maintained their Buy rating on Immix Biopharma's stock with a price target of $30.00.The price target implies an upside of 161.6% from the Sep 28 close of $11.47.Key takeaways from the analyst noteStrong Clinical Results: Immix Biopharma has reported an impressive 89% complete response (CR…